Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 3968

Sort by

Sort Order Select

Journal Articles

Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study

Julio C. Chavez, Michael Dickinson, Javier Munoz, Matthew L. Ulrickson, Catherine Thieblemont, Olalekan O. Oluwole, Alex F. Herrera, Chaitra S. Ujjani, Yi Lin, Peter A. Riedell, Natasha Kekre, Sven de Vos, Jacob Wulff, Chad M. Williams, Joshua Winters, Ioana Kloos, Hairong Xu, Sattva S. Neelapu

Blood (2025) 145 (20): 2303–2311.

https://doi.org/10.1182/blood.2024027347

Published: 2025

Includes: Supplemental data

Journal Articles

Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma

Evangelos Terpos, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Ioannis V. Kostopoulos, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Vasiliki Spiliopoulou, Magdalini Migkou, Despina Fotiou, Foteini Theodorakakou, Efstathios Kastritis, Maria Gavriatopoulou, Ourania E. Tsitsilonis, Meletios-Athanasios Dimopoulos

Blood (2025) 145 (20): 2353–2360.

https://doi.org/10.1182/blood.2024027686

Published: 2025

Journal Articles

Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT

Zachariah DeFilipp, Haesook T. Kim, Laura W. Knight, Suzanne M. O’Connor, Shilton E. Dhaver, Meghan White, Bhagirathbhai Dholaria, Mark A. Schroeder, Sumithira Vasu, Sameem Abedin, Jooho Chung, Areej El-Jawahri, Matthew J. Frigault, Steven McAfee, Richard A. Newcomb, Paul V. O’Donnell, Thomas R. Spitzer, Yi-Bin Chen, Gabriela S. Hobbs

Blood (2025) 145 (20): 2312–2316.

https://doi.org/10.1182/blood.2024028005

Published: 2025

Includes: Supplemental data

Journal Articles

A phase 2 Trial of CHOP with Anti-CCR4 Antibody Mogamulizumab for older Patients with Adult T-Cell Leukemia/Lymphoma

Blood blood.2024027902.

https://doi.org/10.1182/blood.2024027902

Published: 2025

Includes: Supplemental data

Journal Articles

Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from the FRENVEX group

Vincent Jachiet, Olivier Kosmider, Maxime Beydon, Jerome Hadjadj, Lin-Pierre Zhao, Vincent Grobost, Valentin Lacombe, Guillaume Le Guenno, Yann Nguyen, Jean Benoit Arlet, Jeremie Dion, Mael Heiblig, Alice Garnier, Maxime Samson, Achille Aouba, Sylvain Thepot, Sophie Dimicoli-Salazar, Fabien Dutasta, Benoit Faucher, Estibaliz Lazaro, Pr, Veronique Morel, Antoine Neel, Roderau Outh, Holy Bezanahary, Julien Rossignol, Anne-Sophie Alary, Audrey Bidet, Pauline Blateau, Anne Bouvier, Guilaine Boursier, Matthieu Decamp, Benjamin Lebecque, Yannick Le Bris, Pierre Sujobert, Alice Marceau-Renaut, Cedric Pastoret, David Rizzo, Nathalie Boiret-Dupré, Lara Boucher, Stéphanie Dulucq, Franck Genevieve, Cassandra Jadeau, Pierre Lemaire, Romain Vazquez, Jean Baptiste Rieu, Olivier Fain, Sophie Anne Georgin-Lavialle, Pr, Lucie Rigolot, Lise Larcher, Pierre Hirsch, Benjamin Terrier, Pierre Fenaux, Arsène M Mékinian, Thibault Comont

Blood blood.2024028133.

https://doi.org/10.1182/blood.2024028133

Published: 2025

Includes: Supplemental data

Journal Articles

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD –mutated AML

Blood (2025) 145 (19): 2138–2148.

https://doi.org/10.1182/blood.2024025154

Published: 2025

Includes: Supplemental data

Journal Articles

Phase 1/2 Study of High-Dose Palifermin for GVHD Prophylaxis in Patients Undergoing HLA-Matched Unrelated Donor HCT

Eduard Schulz, Lauren M. Curtis, Noa G. Holtzman, Jennifer Sponaugle, Kaska Wloka, Alen Ostojic, Alain Mina, Najla El Jurdi, Filip Pirsl, Ashley Carpenter, Mahshid Golagha, Arlene Sirajuddin, Theo Heller, Brian C. Shaffer, Frances T. Hakim, Jeffrey Steven Rubin, Ronald E. Gress, Steven Z. Pavletic

Blood blood.2024028303.

https://doi.org/10.1182/blood.2024028303

Published: 2025

Includes: Supplemental data

Journal Articles

Targeting CD38 with Daratumumab for Platelet Transfusion Refractoriness in Aplastic Anemia

Zhen Gao, Hong Pan, Lele Zhang, Weiwang Li, Ruonan Li, Jingyu Zhao, Yuechen Luo, Yu Lian, Xiao Yu, Zhexiang Kuang, Neng Nie, Jianping Li, Jinbo Huang, Xin Zhao, Yuan Li, Liwei Fang, Meili Ge, Yizhou Zheng, Jun Shi

Blood blood.2025029006.

https://doi.org/10.1182/blood.2025029006

Published: 2025

Includes: Supplemental data

Journal Articles

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

Blood blood.2025028357.

https://doi.org/10.1182/blood.2025028357

Published: 2025

Includes: Supplemental data

Journal Articles

Long-term outcomes with single-agent BRAF inhibitor therapy in Erdheim-Chester disease

Gaurav Goyal, Anne S. Reiner, Dana Bossert, Allison M. Sigler, Mario E. Lacouture, Veronica Rotemberg, Jasmine H. Francis, Ronald S. Go, Raajit K. Rampal, Eli L. Diamond

Blood (2025) 145 (18): 2100–2103.

https://doi.org/10.1182/blood.2024028032

Published: 2025

Includes: Supplemental data

Journal Articles

Donor regulatory T-cell therapy to prevent graft-versus-host disease

Blood (2025) 145 (18): 2012–2024.

https://doi.org/10.1182/blood.2024026446

Published: 2025

Includes: Supplemental data

Journal Articles

Counterpoint: The Design and Interpretation of Blood Transfusion Randomized Clinical Trials

Jeffrey L Carson, Paul C Hebert, John H Alexander

Blood blood.2025029042.

https://doi.org/10.1182/blood.2025029042

Published: 2025

Journal Articles

A phase 2 randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myeloma

Blood blood.2024027873.

https://doi.org/10.1182/blood.2024027873

Published: 2025

Includes: Supplemental data

Journal Articles

CAR T cells in autoimmunity: game changer or stepping stone?

Dimitrios Mougiakakos, Everett H. Meyer, Georg Schett

Blood (2025) 145 (17): 1841–1849.

https://doi.org/10.1182/blood.2024025413

Published: 2025

Includes: Supplemental data

Journal Articles

Prognostic and therapeutic implications of measurable residual disease levels during remission induction of childhood ALL

Blood (2025) 145 (17): 1890–1902.

https://doi.org/10.1182/blood.2024026381

Published: 2025

Includes: Supplemental data

Journal Articles

Glucarpidase for treatment of high-dose methotrexate toxicity

Shruti Gupta, Sarah A. Kaunfer, Kevin L. Chen, Julie-Alexia Dias, Anitha Vijayan, Arun Rajasekaran, Jason M. Prosek, Huong L. Truong, Anthony Wood, Claude Bassil, Amanda D. Renaghan, Chintan V. Shah, Jingjing Zhang, Ilya Glezerman, Christopher Carlos, Katherine Kelly, Christopher J. Passero, Jan Drappatz, Ala Abudayyeh, Daniel Sanghoon Shin, C. John Sperati, Bradley J. Yelvington, Swetha R. Kanduri, Javier A. Neyra, Daniel Edmonston, Anushree C. Shirali, Anip Bansal, Abdallah Geara, Zain Mithani, Susan L. Ziolkowski, Arash Rashidi, Jonathan Jakubowski, Ashwini Pujari, David A. Bond, Emily Dotson, Sarah Wall, John Patton, Jason N. Barreto, Sandra M. Herrmann, Mohammad S. Sheikh, Rachid Baz, Jamie Lee, Nicholas Lucchesi, Michael Kolman, Muhammad Ahsan Rasheed, Afsheen Afzal, Dasol Kang, Amrita Mahesh, Raymond K. Hsu, Anthony Nicolaysen, Kibrewessen Tefera, Claire Schretlen, Ryan M. Miller, Juan Carlos Velez, Alexander H. Flannery, Abinet M. Aklilu, Shuchi Anand, Soniya Chandrasekhara, Vicki Donley, Ashka Patel, Jian Ni, Shobana Krishnamurthy, Rafia Ali, Osman A. Yilmam, Sophia L. Wells, Jessica L. Ortega, Olivia L. Green-Lingren, Rebecca K. Leaf, Meghan E. Sise, Lakshmi Nayak, Ann S. LaCasce, Nelson Leung, David E. Leaf

Blood (2025) 145 (17): 1858–1869.

https://doi.org/10.1182/blood.2024026211

Published: 2025

Includes: Supplemental data

Journal Articles

Common hereditary variants of the APOE gene and posttransplant outcome in acute myeloid leukemia

Blood (2025) 145 (17): 1943–1956.

https://doi.org/10.1182/blood.2024026886

Published: 2025

Includes: Supplemental data

Journal Articles

Venetoclax plus daunorubicin and cytarabine for newly diagnosed acute myeloid leukemia: results of a phase 1b study

Blood (2025) 145 (17): 1870–1875.

https://doi.org/10.1182/blood.2024026700

Published: 2025

Includes: Supplemental data

Journal Articles

How I diagnose and treat myeloid/lymphoid neoplasms with tyrosine kinase gene fusions

Andreas Reiter, Georgia Metzgeroth, Nicholas C. P. Cross

Blood (2025) 145 (16): 1758–1768.

https://doi.org/10.1182/blood.2023022417

Published: 2025

Journal Articles

Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial

Blood (2025) 145 (16): 1780–1787.

https://doi.org/10.1182/blood.2024027342

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study

Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma

Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT

A phase 2 Trial of CHOP with Anti-CCR4 Antibody Mogamulizumab for older Patients with Adult T-Cell Leukemia/Lymphoma

Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from the FRENVEX group

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD –mutated AML

Phase 1/2 Study of High-Dose Palifermin for GVHD Prophylaxis in Patients Undergoing HLA-Matched Unrelated Donor HCT

Targeting CD38 with Daratumumab for Platelet Transfusion Refractoriness in Aplastic Anemia

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

Long-term outcomes with single-agent BRAF inhibitor therapy in Erdheim-Chester disease

Donor regulatory T-cell therapy to prevent graft-versus-host disease

Counterpoint: The Design and Interpretation of Blood Transfusion Randomized Clinical Trials

A phase 2 randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myeloma

CAR T cells in autoimmunity: game changer or stepping stone?

Prognostic and therapeutic implications of measurable residual disease levels during remission induction of childhood ALL

Glucarpidase for treatment of high-dose methotrexate toxicity

Common hereditary variants of the APOE gene and posttransplant outcome in acute myeloid leukemia

Venetoclax plus daunorubicin and cytarabine for newly diagnosed acute myeloid leukemia: results of a phase 1b study

How I diagnose and treat myeloid/lymphoid neoplasms with tyrosine kinase gene fusions

Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only